Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT

Steven M. Kawut, Emilia Bagiella, Daichi Shimbo, David J. Lederer, Nadine Al-Naamani, Kari E. Roberts, R. Graham Barr, Wendy S Post, Evelyn M. Horn, Russell Tracy, Paul M Hassoun, Reda Girgis

Research output: Contribution to journalArticle

Abstract

Background: Pulmonary arterial hypertension (PAH) is a progressive disease which causes exercise limitation, heart failure, and death. Aspirin and simvastatin are highly effective and safe therapies for other cardiovascular diseases characterized by platelet activation and endothelial dysfunction, but have not been formally studied in PAH. Methods: ASA-STAT is a phase II, randomized, double-blind, placebo-controlled 2×2 factorial clinical trial of aspirin and simvastatin in patients with PAH. A total of 92 subjects were to be randomized to aspirin or aspirin placebo and simvastatin or simvastatin placebo. The primary outcome is the distance walked in 6 min at 6 months after randomization. Secondary measures include brachial artery flow-mediated dilation, circulating biomarkers of platelet and endothelial function, functional class, quality-of-life, and time to clinical end points. The incidence of adverse events will be compared between treatment groups. Screening and enrollment: We screened a total of 712 individuals with PAH. Sixty-five subjects were enrolled when the trial was terminated for futility in reaching the primary end point for simvastatin. Conclusions: This study aims to determine whether aspirin or simvastatin have beneficial biologic or clinical effects in patients with PAH. The safety and side effects of these commonly prescribed cardiovascular drugs will also be assessed.

Original languageEnglish (US)
Pages (from-to)280-287
Number of pages8
JournalContemporary Clinical Trials
Volume32
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Phase II Clinical Trials
Simvastatin
Pulmonary Hypertension
Aspirin
Placebos
Therapeutics
Medical Futility
Cardiovascular Agents
Brachial Artery
Platelet Activation
Random Allocation
Dilatation
Cardiovascular Diseases
Blood Platelets
Heart Failure
Biomarkers
Quality of Life
Clinical Trials
Exercise
Safety

Keywords

  • Clinical trial
  • Endothelial dysfunction
  • Platelets
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension : ASA-STAT. / Kawut, Steven M.; Bagiella, Emilia; Shimbo, Daichi; Lederer, David J.; Al-Naamani, Nadine; Roberts, Kari E.; Barr, R. Graham; Post, Wendy S; Horn, Evelyn M.; Tracy, Russell; Hassoun, Paul M; Girgis, Reda.

In: Contemporary Clinical Trials, Vol. 32, No. 2, 03.2011, p. 280-287.

Research output: Contribution to journalArticle

Kawut, SM, Bagiella, E, Shimbo, D, Lederer, DJ, Al-Naamani, N, Roberts, KE, Barr, RG, Post, WS, Horn, EM, Tracy, R, Hassoun, PM & Girgis, R 2011, 'Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT', Contemporary Clinical Trials, vol. 32, no. 2, pp. 280-287. https://doi.org/10.1016/j.cct.2010.12.005
Kawut, Steven M. ; Bagiella, Emilia ; Shimbo, Daichi ; Lederer, David J. ; Al-Naamani, Nadine ; Roberts, Kari E. ; Barr, R. Graham ; Post, Wendy S ; Horn, Evelyn M. ; Tracy, Russell ; Hassoun, Paul M ; Girgis, Reda. / Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension : ASA-STAT. In: Contemporary Clinical Trials. 2011 ; Vol. 32, No. 2. pp. 280-287.
@article{1aa1114945a949e98a2ec572c69cbb59,
title = "Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT",
abstract = "Background: Pulmonary arterial hypertension (PAH) is a progressive disease which causes exercise limitation, heart failure, and death. Aspirin and simvastatin are highly effective and safe therapies for other cardiovascular diseases characterized by platelet activation and endothelial dysfunction, but have not been formally studied in PAH. Methods: ASA-STAT is a phase II, randomized, double-blind, placebo-controlled 2×2 factorial clinical trial of aspirin and simvastatin in patients with PAH. A total of 92 subjects were to be randomized to aspirin or aspirin placebo and simvastatin or simvastatin placebo. The primary outcome is the distance walked in 6 min at 6 months after randomization. Secondary measures include brachial artery flow-mediated dilation, circulating biomarkers of platelet and endothelial function, functional class, quality-of-life, and time to clinical end points. The incidence of adverse events will be compared between treatment groups. Screening and enrollment: We screened a total of 712 individuals with PAH. Sixty-five subjects were enrolled when the trial was terminated for futility in reaching the primary end point for simvastatin. Conclusions: This study aims to determine whether aspirin or simvastatin have beneficial biologic or clinical effects in patients with PAH. The safety and side effects of these commonly prescribed cardiovascular drugs will also be assessed.",
keywords = "Clinical trial, Endothelial dysfunction, Platelets, Pulmonary hypertension",
author = "Kawut, {Steven M.} and Emilia Bagiella and Daichi Shimbo and Lederer, {David J.} and Nadine Al-Naamani and Roberts, {Kari E.} and Barr, {R. Graham} and Post, {Wendy S} and Horn, {Evelyn M.} and Russell Tracy and Hassoun, {Paul M} and Reda Girgis",
year = "2011",
month = "3",
doi = "10.1016/j.cct.2010.12.005",
language = "English (US)",
volume = "32",
pages = "280--287",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension

T2 - ASA-STAT

AU - Kawut, Steven M.

AU - Bagiella, Emilia

AU - Shimbo, Daichi

AU - Lederer, David J.

AU - Al-Naamani, Nadine

AU - Roberts, Kari E.

AU - Barr, R. Graham

AU - Post, Wendy S

AU - Horn, Evelyn M.

AU - Tracy, Russell

AU - Hassoun, Paul M

AU - Girgis, Reda

PY - 2011/3

Y1 - 2011/3

N2 - Background: Pulmonary arterial hypertension (PAH) is a progressive disease which causes exercise limitation, heart failure, and death. Aspirin and simvastatin are highly effective and safe therapies for other cardiovascular diseases characterized by platelet activation and endothelial dysfunction, but have not been formally studied in PAH. Methods: ASA-STAT is a phase II, randomized, double-blind, placebo-controlled 2×2 factorial clinical trial of aspirin and simvastatin in patients with PAH. A total of 92 subjects were to be randomized to aspirin or aspirin placebo and simvastatin or simvastatin placebo. The primary outcome is the distance walked in 6 min at 6 months after randomization. Secondary measures include brachial artery flow-mediated dilation, circulating biomarkers of platelet and endothelial function, functional class, quality-of-life, and time to clinical end points. The incidence of adverse events will be compared between treatment groups. Screening and enrollment: We screened a total of 712 individuals with PAH. Sixty-five subjects were enrolled when the trial was terminated for futility in reaching the primary end point for simvastatin. Conclusions: This study aims to determine whether aspirin or simvastatin have beneficial biologic or clinical effects in patients with PAH. The safety and side effects of these commonly prescribed cardiovascular drugs will also be assessed.

AB - Background: Pulmonary arterial hypertension (PAH) is a progressive disease which causes exercise limitation, heart failure, and death. Aspirin and simvastatin are highly effective and safe therapies for other cardiovascular diseases characterized by platelet activation and endothelial dysfunction, but have not been formally studied in PAH. Methods: ASA-STAT is a phase II, randomized, double-blind, placebo-controlled 2×2 factorial clinical trial of aspirin and simvastatin in patients with PAH. A total of 92 subjects were to be randomized to aspirin or aspirin placebo and simvastatin or simvastatin placebo. The primary outcome is the distance walked in 6 min at 6 months after randomization. Secondary measures include brachial artery flow-mediated dilation, circulating biomarkers of platelet and endothelial function, functional class, quality-of-life, and time to clinical end points. The incidence of adverse events will be compared between treatment groups. Screening and enrollment: We screened a total of 712 individuals with PAH. Sixty-five subjects were enrolled when the trial was terminated for futility in reaching the primary end point for simvastatin. Conclusions: This study aims to determine whether aspirin or simvastatin have beneficial biologic or clinical effects in patients with PAH. The safety and side effects of these commonly prescribed cardiovascular drugs will also be assessed.

KW - Clinical trial

KW - Endothelial dysfunction

KW - Platelets

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=79551554855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551554855&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2010.12.005

DO - 10.1016/j.cct.2010.12.005

M3 - Article

C2 - 21146637

AN - SCOPUS:79551554855

VL - 32

SP - 280

EP - 287

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 2

ER -